Hypoxia-inducible factor for the treatment of anemia in chronic kidney disease

• Main Author: O.O. Melnyk
• Format: Article
• Language: English
• Published: Publishing House Zaslavsky 2018-10-01
• Series: Počki
• Subjects: anemia; chronic kidney disease; hypoxia-inducible factor; prolyl hydroxylase inhibitor; roxadustat; vadadustat; daprodustat; molidustat; review
• Online Access: http://kidneys.zaslavsky.com.ua/article/view/148522

Studies in the field of oxygen-dependent regulation of erythropoiesis provided new data on the pathogenesis of anemia associated with chronic kidney disease, which led to the development of therapeutic agents for treatment. A new class of agents for the treatment of anemia in chronic kidney disease are prolyl hydroxylase inhibitors, which stabilize hypoxia-inducible factor that is the key regulator of erythropoiesis and iron metabolism. Currently, drugs such as roxadustat (FG-4592), vadadustat (AKB-6548), daprodustat (GSK1278863) are undergoing phase III clinical trials, and molidustat (BAY 85-3934) — phase II.